Clascoterone for Steroid-related Acne Vulgaris in Transgender Male Patients Receiving Masculinizing Hormone Therapy

Inclusion Criteria

• •transgender male or gender diverse patient on MHT
• •on a stable dose of MHT for at least 3 months prior to the study
• •anticipate being on the same dose of MHT for the duration of the study
• •have steroid-related acne vulgaris as determined by the investigator with onset or worsening after initiation of MHT
• •have at least 20 papules or pustules on the face
• •consistent skin care regimen (topical and systemic medications) for at least 4 weeks prior to enrollment and continue it for the duration of the study (however, note exclusion below that topical steroids on face not allowed for 4 weeks prior to enrollment and during study)\*;
• •age 16 years old or older
• •potential participants who have ovaries and are or planning to be sexually active with partners that produce sperm will need to use a medically reliable form of birth control (including but not limited to condoms, intrauterine device, oral contraceptives) before enrollment and during the study
• •* Note inhaled steroids are allowed as long as regimen is stable one month prior to enrollment and during the study